Advertisement

Ads Placeholder
Loading...

Emergent BioSolutions Inc.

EBS•NYSE
Healthcare
Drug Manufacturers - Specialty & Generic
$8.24
$0.28(3.52%)
U.S. Market opens in 16h 46m

Emergent BioSolutions Inc. (EBS) Stock Overview

Explore Emergent BioSolutions Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

Z

Key Financials

Market Cap426.1M
P/E Ratio8.16
EPS (TTM)$0.93
ROE0.10%
Fundamental Analysis

AI Price Forecasts

1 Month$9.20
3 Months$9.90
1 Year Target$12.35

EBS Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Emergent BioSolutions Inc. (EBS) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 40.27, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $12.35.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 8.16 and a market capitalization of 426.1M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
3.39%
5-Day Change
0.98%
1-Month Change
1.98%
3-Month Change
-32.37%
6-Month Change
-11.51%
Year-to-Date (YTD) Change
-34.21%
1-Year Change
79.69%
3-Year Change
-34.79%
5-Year Change
-88.69%
All-Time (Max) Change
-29.66%

Contact Information

https://www.emergentbiosolutions.com
240 631 3200
400 Professional Drive, Gaithersburg, MD, 20879

Company Facts

900 Employees
IPO DateNov 15, 2006
CountryUS
Actively Trading

Frequently Asked Questions